Ipamorelin Dosage: Timing, Cycling, and Safety

Ipamorelin has no FDA-approved dosage because it has never completed the regulatory approval process for any indication. The doses that appear in published human and animal research range widely depending on the study’s goals, and the pharmacokinetic modeling that does exist shows substantial person-to-person variability in growth hormone response to the same amount of peptide. That variability, combined with the peptide’s relatively short half-life and unique selectivity profile, makes the dosing picture more nuanced than a single number can capture.

What Makes Ipamorelin Different From Other Growth Hormone Secretagogues

Ipamorelin belongs to a family of peptides called growth hormone releasing peptides, which stimulate the pituitary gland to release growth hormone. What sets it apart is selectivity. In animal and human studies, ipamorelin triggers growth hormone release without raising cortisol or prolactin levels, hormones that other secretagogues in the same class tend to bump up.¹ That matters because chronically elevated cortisol promotes fat storage and muscle breakdown, while elevated prolactin can interfere with sexual function. The fact that ipamorelin avoids both gives it a cleaner side-effect profile at the doses researchers have studied.

In laboratory comparisons, ipamorelin stimulates growth hormone release with potency and effectiveness comparable to GHRP-6, one of the older and more widely studied peptides in this class.² The difference is that GHRP-6 also stimulates appetite and can raise cortisol. Ipamorelin achieves a similar magnitude of growth hormone output without those secondary hormonal effects, which is why it earned the label “the first selective growth hormone secretagogue” in the research literature.

What Human Pharmacokinetic Studies Reveal About Dosing

The most detailed human dose-response data come from pharmacokinetic modeling in healthy volunteers. After subcutaneous injection, ipamorelin shows dose-proportional behavior, meaning that doubling the dose roughly doubles the blood concentration. The terminal half-life sits around two hours, which is short enough that the peptide clears the body relatively quickly after each dose.³

Growth hormone release follows a single sharp peak about 40 minutes after injection, then drops back toward baseline. This pattern held across all dose levels tested, and growth hormone production was stimulated at every dose studied. The modeling estimated that the plasma concentration needed to reach half of the maximum growth hormone output was about 214 nmol/L, and the maximum growth hormone production rate was about 694 mIU/L per hour.⁴ In practical terms, this means there is a ceiling: once you have enough ipamorelin circulating, pushing the dose higher does not produce proportionally more growth hormone. You get diminishing returns past a certain point.

One finding from that same modeling work deserves emphasis. Individual subjects varied considerably in how much growth hormone they produced from the same dose. This variability is well documented and is one reason why a single “correct” dose cannot be stated universally. Age, sex, body composition, and baseline pituitary function all influence the response.

Timing, Frequency, and the Pulsatile Nature of Growth Hormone

Your body releases growth hormone in pulses, not as a steady stream. The largest natural pulse happens during deep sleep, with smaller bursts scattered through the day. Ipamorelin works by amplifying these pulses rather than overriding them, which is part of why it produces a more physiological growth hormone profile compared to injecting synthetic growth hormone directly.

Because ipamorelin’s half-life is about two hours and the growth hormone peak fades within a couple of hours after that, most research protocols and clinical guidance involve multiple daily injections, often two to three, to generate repeated growth hormone pulses through the day. Timing one dose before bed aligns with the body’s natural nighttime growth hormone surge. A common research approach spaces doses so they do not overlap, giving the pituitary time to recharge between pulses. Injecting too frequently can blunt the response because the pituitary needs time to replenish its stored growth hormone before it can release another burst.

Food intake matters too. Elevated blood sugar and insulin suppress growth hormone release. For that reason, injections are typically timed on an empty stomach or at least 90 minutes after eating. This is not unique to ipamorelin; it applies to the entire class of growth hormone secretagogues.

Subcutaneous Injection Versus Other Routes

Nearly all published research uses subcutaneous injection, which delivers the peptide efficiently into the bloodstream. However, nasal administration has also been studied. In animal pharmacokinetic work, intranasal ipamorelin achieved a bioavailability of roughly 20%, meaning only about a fifth of the dose reaches systemic circulation compared to injection.⁵ That is actually a respectable number for a peptide administered through the nose. Most peptides are broken down too quickly in the nasal mucosa to be useful by that route. Still, the fivefold reduction in bioavailability means nasal dosing would require a significantly larger amount to achieve the same growth hormone response as a subcutaneous injection.

Intravenous administration has been used in some clinical studies, particularly the postoperative ileus trials, where hospital settings made IV delivery practical. For people outside a clinical setting, subcutaneous injection remains the standard route in the research literature.

Cycling and Receptor Sensitivity

A recurring concern with any peptide that stimulates a receptor repeatedly is desensitization: the receptor stops responding as strongly over time. With ipamorelin, the general practice in research protocols involves cycling periods of use with periods off, often in the range of eight to twelve weeks of administration followed by four to eight weeks without it. The goal is to keep the pituitary’s growth hormone releasing peptide receptors sensitive so that each dose continues to produce a meaningful growth hormone pulse.

Whether this desensitization actually occurs with ipamorelin at the doses used in research has not been rigorously studied in long-duration human trials. The cycling recommendation is partly borrowed from experience with other secretagogues and partly based on the general pharmacological principle that chronic receptor stimulation leads to downregulation. It is a reasonable precaution, but it is not backed by the kind of controlled human data that would let anyone specify the exact optimal cycle length.

Combining Ipamorelin With CJC-1295 or Other GHRH Analogs

Growth hormone release from the pituitary is controlled by two opposing signals: growth hormone releasing hormone (GHRH), which says “release more,” and somatostatin, which says “stop releasing.” Ipamorelin works primarily on the ghrelin receptor side, amplifying the release signal. GHRH analogs like CJC-1295 work on the other arm, directly stimulating the GHRH receptor. When both arms are activated simultaneously, the result in preclinical studies is a growth hormone response larger than you would get from simply adding together the effects of each agent alone. This synergistic pattern was documented with earlier GHRPs in the 1990s and has been replicated with ipamorelin and CJC-1295 combinations in animal models.

The practical consequence is that combination protocols often use lower doses of each individual peptide than would be needed if either were used alone. CJC-1295 in its DAF-modified form has a much longer half-life (days rather than hours), so it provides a sustained baseline GHRH signal that ipamorelin’s short pulses ride on top of. This combination has become one of the most widely discussed in peptide therapy circles, but the dosing ratios come from clinical practice rather than from large randomized trials. The evidence base is thinner than many online guides suggest.

Side Effects and Safety at Studied Doses

The most controlled safety data come from a randomized, placebo-controlled trial in patients recovering from bowel surgery. In that study, the overall rate of any side effect was actually slightly lower in the ipamorelin group (about 88%) than in the placebo group (about 95%).⁶ That does not mean ipamorelin has zero side effects; it means the peptide did not add measurably to the side effects these surgical patients were already experiencing. In that specific context, ipamorelin appeared well tolerated.

The most commonly reported side effects in broader use include mild headache, transient flushing, and occasional lightheadedness shortly after injection. These tend to be dose-related and short-lived. Because ipamorelin does not significantly raise cortisol or prolactin, it avoids the water retention, hunger spikes, and mood changes associated with less selective secretagogues like GHRP-6 or GHRP-2.⁷

One effect worth knowing about: ipamorelin can stimulate insulin release from the pancreas, as demonstrated in both normal and diabetic rat models.⁸ Growth hormone itself tends to raise blood sugar over time, so the net metabolic effect in humans is not straightforward. People with diabetes or insulin resistance should be aware that ipamorelin could influence their blood sugar regulation in unpredictable ways.

Why Self-Directed Dosing Is Riskier Than It Looks

Online forums frequently cite specific microgram amounts as “standard” ipamorelin doses, often 200 to 300 micrograms per injection two to three times daily. These numbers circulate widely, but they are not drawn from any pivotal clinical trial establishing an optimal dose for a specific outcome in a defined population. They represent a rough consensus among clinicians and researchers working with the peptide, influenced by the pharmacokinetic modeling data and practical experience.

The pharmacokinetic research makes one thing clear: the same dose produces meaningfully different growth hormone responses in different people.⁹ Someone with robust pituitary function might get a large growth hormone spike from a moderate dose, while someone with age-related decline in pituitary reserves might get a muted response from the same amount. Without measuring IGF-1 levels (the downstream marker that reflects growth hormone activity over time) or growth hormone itself, you are essentially guessing whether a given dose is doing what you want.

This is not a theoretical concern. Growth hormone excess, even when produced by your own pituitary, can cause joint pain, carpal tunnel symptoms, fluid retention, and over long periods, potentially increase the risk of certain health problems. The fact that ipamorelin stimulates your own growth hormone rather than injecting synthetic growth hormone directly provides some built-in safety margin, because the pituitary has its own feedback mechanisms. But those mechanisms can be overwhelmed with high enough doses or prolonged enough use.

Effects on Bone That Relate to Dosing Duration

Some of the most interesting dosing data come from bone research in animal models. When adult female rats received ipamorelin three times daily for 15 days at escalating doses, the peptide increased longitudinal bone growth in a clear dose-dependent fashion, from 42 micrometers per day in controls up to 52 micrometers per day at the highest dose.¹⁰ Separately, ipamorelin and GHRP-6 both increased bone mineral content in adult female rats as measured by imaging, with the gains coming from increased bone dimensions rather than denser bone tissue.¹¹

Perhaps more relevant for people on glucocorticoid medications: when rats given corticosteroids (which are known to weaken bones and muscles) also received ipamorelin, the peptide counteracted the bone formation decline. Periosteal bone formation rate jumped roughly fourfold compared to animals on corticosteroids alone, and muscle strength also improved.¹² These are animal findings and cannot be directly translated to human dosing, but they illustrate that the bone-related effects depend on sustained treatment over days to weeks, not a single dose. Anyone considering ipamorelin for bone-related purposes should understand that this is among the least well-studied applications in humans.

Gut Motility and the Postoperative Dosing Context

The clinical setting where ipamorelin has been studied most formally is postoperative ileus, the sluggish gut that often follows abdominal surgery. Ipamorelin mimics ghrelin, and the ghrelin receptor plays a role in gut motility. In a rodent model of postoperative ileus, ipamorelin at an intravenous dose of 0.014 micromoles per kilogram significantly accelerated gastric emptying. Roughly 52% of a test meal remained in the stomach after treatment, compared to 78% in untreated surgical controls and 44% in animals that never had surgery.¹³ The human proof-of-concept trial in bowel resection patients used intravenous dosing in a hospital setting, which is a very different context from the subcutaneous self-injection most people reading about ipamorelin dosage have in mind.¹⁴

The gut motility research matters for the dosing conversation because it shows that ipamorelin’s effects extend beyond growth hormone release. The ghrelin receptor is expressed throughout the digestive tract, and stimulating it has consequences for digestion and appetite. At common subcutaneous doses used for body composition purposes, some users report improved digestion or reduced bloating, which aligns with the gastric motility data even though those subjective reports come from anecdote rather than controlled trials.

Body Composition Evidence and Its Limits

Ipamorelin is frequently marketed for fat loss and muscle gain, but the human evidence base for these outcomes is surprisingly thin. A review examining growth hormone secretagogues in the context of low testosterone noted that ipamorelin and related peptides are potent stimulators of growth hormone and IGF-1 and could improve body composition, but acknowledged a “paucity of data” examining the actual clinical effects.¹⁵ Growth hormone itself does promote fat breakdown and lean mass retention, so the logic that stimulating more growth hormone should improve body composition is pharmacologically sound. The gap is in controlled human trials demonstrating specific body composition changes at specific ipamorelin doses over defined time periods. Those studies largely do not exist yet.

This is worth keeping in mind when evaluating the dose recommendations you encounter online. Many are extrapolated from the known dose-response relationship for growth hormone release and from clinical experience rather than from trials measuring the downstream outcomes people actually care about, like reduced body fat percentage or increased lean mass. The dose that maximizes a growth hormone spike on a blood test is not necessarily the dose that produces the best body composition result over weeks or months.

Anti-Doping Detection and Competitive Athletes

Ipamorelin is banned by the World Anti-Doping Agency under the category of growth hormone secretagogues. Detection methods have become increasingly sophisticated. After nasal administration to volunteers, ipamorelin was found to metabolize extensively, but a specific metabolite (ipamorelin 1-4 free acid) remained detectable in urine even after the parent compound had cleared entirely.¹⁶ More recently, a method using dried blood spots demonstrated sensitive detection of ipamorelin at very low concentrations, allowing anti-doping labs to identify use from a simple finger-prick blood sample.¹⁷

For competitive athletes, the takeaway is straightforward: ipamorelin is detectable through multiple testing matrices, the detection window extends beyond what the two-hour half-life might suggest, and anti-doping laboratories have incorporated both the parent peptide and its metabolites into routine screening. The peptide’s short half-life does not make it invisible to testing.

What Has Not Been Studied

The honest assessment of ipamorelin dosing is that most of the pharmacological groundwork has been laid, but the clinical follow-through has stalled. The pharmacokinetics in humans are well characterized. The selectivity profile is genuinely impressive compared to older secretagogues. The animal data on bone, gut motility, and growth hormone release are robust. What is missing are large, long-duration human trials establishing optimal doses for specific outcomes like body composition change, bone density improvement, or sleep quality enhancement. The postoperative ileus program, which represented the most advanced clinical development effort, did not progress to approval. Until more human efficacy data accumulate, dosing will remain a matter of clinical judgment informed by pharmacokinetic principles rather than evidence-based guidelines tied to measurable endpoints.